Enanta Pharmaceuticals Inc (ENTA) — SEC Filings
Enanta Pharmaceuticals Inc (ENTA) — 36 SEC filings. Latest: 8-K (Mar 26, 2026). Includes 16 8-K, 7 SC 13G/A, 6 10-Q.
View Enanta Pharmaceuticals Inc on SEC EDGAR
Overview
Enanta Pharmaceuticals Inc (ENTA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Enanta Pharmaceuticals Inc. filed an 8-K on March 26, 2026, reporting an "Other Event" under Item 8.01 related to its period of report ending March 20, 2026. While the filing itself doesn't detail the specific event, it signals that something noteworthy occurred that the company deemed important eno
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 1 bullish, 33 neutral, 2 mixed. The dominant filing sentiment for Enanta Pharmaceuticals Inc is neutral.
Filing Type Overview
Enanta Pharmaceuticals Inc (ENTA) has filed 16 8-K, 2 10-K, 6 10-Q, 2 DEFA14A, 2 DEF 14A, 7 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of ENTA's 24 recent filings, 1 were flagged as high-risk, 4 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not Disclosed |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | $188.9 million |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Sarah Johnson
- John Smith
- Principal Executive Officer (PEO)
- Dr. Jay L. D. Weinstein
- Dr. Sarah J. De Bruin
Industry Context
Enanta Pharmaceuticals operates in the competitive biotechnology sector, focusing on virology and immunology. The company leverages its chemistry-driven discovery approach to develop small molecule drugs. Key areas include the established HCV market, where MAVYRET/MAVIRET is a significant player, and the growing RSV market with substantial unmet needs. The immunology pipeline targets large, potentially lucrative markets for type 2 inflammatory diseases.
Top Tags
financial-reporting (7) · pharmaceuticals (6) · sec-filing (5) · 10-Q (5) · 8-K (5) · financials (4) · institutional-ownership (4) · Enanta Pharmaceuticals (3) · amendment (3) · regulatory-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash, cash equivalents, and short-term marketable securities | $188.9 million | As of September 30, 2025, projected to fund operations into fiscal 2029 |
| Portion of MAVYRET/MAVIRET royalties to OMERS | 54.5% | Beginning after June 30, 2023, subject to a 1.42x cap |
| Common stock price per share | $5.52 | As of March 31, 2025, used to calculate market value of non-affiliate shares |
| Aggregate market value of common stock held by non-affiliates | $110,592,792 | As of March 31, 2025 |
| Shares of Common Stock outstanding | 28,862,601 | As of November 4, 2025 |
| Projected market for urticaria | $5 billion | By 2030, highlighting immunology market potential |
| Projected market for Atopic Dermatitis (AD) | $30 billion | By 2030, highlighting immunology market potential |
| Projected combined market for asthma, COPD, CRSwNP, and PN | $35 billion | By 2030, highlighting immunology market potential |
| Annual RSV outpatient visits in the U.S. | 6.5 million | CDC estimate, underscoring RSV market need |
| Annual RSV deaths in the U.S. | 23,000 | CDC estimate, underscoring RSV market severity |
| Net loss for Q3 2025 | $18.255M | Improved from $22.658M in Q3 2024 |
| Net loss for nine months ended June 30, 2025 | $63.189M | Improved from $87.222M in the prior year period |
| Royalty revenue for nine months ended June 30, 2025 | $50.199M | Decreased from $53.028M in the prior year period |
| Total operating expenses for nine months ended June 30, 2025 | $117.162M | Decreased by 19.1% from $144.865M in the prior year period |
| Cash, cash equivalents, and short-term marketable securities as of June 30, 2025 | $204.111M | Expected to fund operations for at least 12 months |
Forward-Looking Statements
- {"claim":"Enanta Pharmaceuticals Inc. will continue to report net losses in the near term due to ongoing high R&D expenditures.","entity":"Enanta Pharmaceuticals Inc.","targetDate":"2024-09-30","confidence":"high"}
- {"claim":"The company's cash and marketable securities will continue to decline if current spending rates persist without new revenue streams.","entity":"Enanta Pharmaceuticals Inc.","targetDate":"2024-06-30","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Enanta Pharmaceuticals Inc (ENTA)?
Enanta Pharmaceuticals Inc has 36 recent SEC filings from Jan 2024 to Mar 2026, including 16 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ENTA filings?
Across 36 filings, the sentiment breakdown is: 1 bullish, 33 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Enanta Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Enanta Pharmaceuticals Inc (ENTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Enanta Pharmaceuticals Inc?
Key financial highlights from Enanta Pharmaceuticals Inc's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ENTA?
The investment thesis for ENTA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Enanta Pharmaceuticals Inc?
Key executives identified across Enanta Pharmaceuticals Inc's filings include Dr. Sarah Johnson, John Smith, Principal Executive Officer (PEO), Dr. Jay L. D. Weinstein, Dr. Sarah J. De Bruin.
What are the main risk factors for Enanta Pharmaceuticals Inc stock?
Of ENTA's 24 assessed filings, 1 were flagged high-risk, 4 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Enanta Pharmaceuticals Inc?
Recent forward-looking statements from Enanta Pharmaceuticals Inc include guidance on {"claim":"Enanta Pharmaceuticals Inc. will continue to report net losses in the near term due to ongoing high R&D expend and 1 other predictions.